Our Science

TRANSFORMING CANCER TREATMENT THROUGH INNOVATION

Our proprietary PREDATOR™ protein engineering technology integrates specialized protein design elements to enhance activity, stability and tumor selectivity within a single molecule. These are called INDUKINE™ molecules.

Systemic Delivery

Tumor Microenvironment

Immune cell receptor

Protease

Half-life extension
domain

Cytokine domain

Inactivation domain

Protease-cleavable linkers

INDUKINE™ molecules are systemically administered in an inactive form and, upon entering the tumor microenvironment, are selectively activated to deliver the full biological potency of cytokines and recruit a powerful anti-tumor immune response. Therefore, INDUKINE™ molecules deliver maximum therapeutic potential while minimizing unwanted off-target effects in non-tumor tissues.

Watch

How PREDATOR™ maximizes therapeutic potential while minimizing unwanted off-target effects

Predator™ Protein Engineering

Our proprietary PREDATOR™ protein engineering technology allows us to achieve immune targeting and conditional activation in a new way, enabling the development of novel therapies designed to:

Exhibit superior tolerability and drug-like properties when administered systemically as inactive pro-drugs

Undergo transformation to the active state only upon reaching the tumor microenvironment

Deliver full biological potency of antitumor immune modulation for maximum therapeutic potential

INNOVATIVE OPPORTUNITIES FOR PREDATOR™ PLATFORM

In addition to our core commitment to oncology, our PREDATOR™ approach allows us to target other immunology-based diseases.

Our PREDATOR™ protein engineering technology allows us to create INDUKINE™ molecules for tissue-specific inflammatory diseases where modulating the immune system can offer therapeutic benefits while minimizing unwanted off-target effects in healthy tissues.

Non-Oncology INDUKINE™ Therapeutics

Inflammation
Other diseases

Expanding Conditional-Activation Technology to New Modalities

Targeted antibodies, T cell engagers, ADCs
Cell-based therapies
Disease-specific linkers